Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) FCF Margin (2019 - 2025)

Eton Pharmaceuticals' FCF Margin history spans 7 years, with the latest figure at 30.71% for Q3 2025.

  • For Q3 2025, FCF Margin rose 211.0% year-over-year to 30.71%; the TTM value through Sep 2025 reached 29.89%, up 2620.0%, while the annual FY2024 figure was 2.42%, 1912.0% down from the prior year.
  • FCF Margin for Q3 2025 was 30.71% at Eton Pharmaceuticals, down from 42.05% in the prior quarter.
  • Across five years, FCF Margin topped out at 139.33% in Q1 2025 and bottomed at 380.9% in Q3 2021.
  • The 5-year median for FCF Margin is 13.83% (2024), against an average of 5.29%.
  • The largest YoY upside for FCF Margin was 1425297bps in 2021 against a maximum downside of -24095071bps in 2021.
  • A 5-year view of FCF Margin shows it stood at 84.05% in 2021, then skyrocketed by 140bps to 33.28% in 2022, then tumbled by -96bps to 1.3% in 2023, then plummeted by -614bps to 6.67% in 2024, then skyrocketed by 560bps to 30.71% in 2025.
  • Per Business Quant, the three most recent readings for ETON's FCF Margin are 30.71% (Q3 2025), 42.05% (Q2 2025), and 139.33% (Q1 2025).